Don t miss the big stories. Like us on Facebook.
(BPT) - Creating a tapestry of vivid colors and patterns, Geri Wires, an avid quilter, relies on her sight to create her art. So, in 2007 after her dilated eye exam and speaking with her eye doctor, she was alarmed at the diagnosis of age-related macular degeneration (AMD) at age 64. AMD is one of the leading causes of vision loss among people 50 and older and affects 16 million Americans â more than glaucoma and cataracts combined.
âAfter my diagnosis, the reality of AMD and its potential effects on my vision became very serious to me,â Wires said. To help manage her condition, Wires began taking Bausch + Lomb PreserVision
Share this article
Results Provide New Evidence of the Recommended Formula Determined in the AREDS2 Study
LAVAL, Quebec, May 11, 2021 /PRNewswire/ Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health ), today announced new data from the National Eye Institute (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), which reaffirms the clinical outcomes of the AREDS2 study. Based on this data, the NEI continues to recommend a specific nutrient formula to help reduce the risk of progression in patients with moderate to advanced Age-Related Macular Degeneration (AMD).
1 That formula is currently found in